AIMS
The impact of tirzepatide and dulaglutide on major adverse cardiovascular events (MACE) and heart failure (HF) outcomes according to HF status is unknown.
METHODS AND RESULTS
Patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease were treated with tirzepatide up to 15 mg or dulaglutide 1....
S. J. Nicholls, I. Pavo, Deepak L. Bhatt et al.· European Journal of Preventi...· 0 citations
BACKGROUND
Influenza vaccination is recommended for cardiovascular secondary prevention, but the comparative effectiveness of different dose strategies remains incompletely characterised.
METHODS
We searched MEDLINE, Embase, and CENTRAL for randomised trials comparing high-dose (HD-IIV), double standard-dose, standar...
Joshua J. Hon, T. Aikawa, T. Biering-Sørensen et al.· American Heart Journal· 0 citations
AIMS
To investigate the association between serial high-sensitivity cardiac troponin-T (hs-TnT) concentrations and subsequent heart failure in individuals presenting with suspected acute coronary syndrome (ACS).
METHODS AND RESULTS
Utilizing Danish nationwide registries, we identified individuals without known heart...
Philip Ahle Erichsen, Majid Afzal, Christina Byrne et al.· International Journal of Car...· 1 citation
Background Cognitive decline has been reported after coronary artery revascularization, but whether it reflects procedure-specific effects or the burden of underlying vascular disease remains uncertain. Objectives To determine whether incident dementia risk differs according to coronary revascularization strategy among...
BACKGROUND
Systemic inflammation has been associated with heart failure (HF) development. C-reactive protein (CRP) is a sensitive marker of inflammation, but its prognostic association with incident HF remains incompletely defined. We explored whether persistent CRP elevation was associated with incident HF among adult...
M. Busti, L. Monzo, T. Rastogi et al.· International Journal of Car...· 1 citation
In patients at high or extreme surgical risk, TAVR with the self-expanding intra-annular transcatheter heart valve had similar 5-year overall survival, stroke rates, and valve function compared with commercially available valves.
Raj R. Makkar, Wen Cheng, Ron Waksman et al.· JACC: Cardiovascular Interve...· 0 citations
Patients with concurrent MR and AS exhibit substantially higher mortality yet have high rates of undertreatment throughout the duration of follow-up, and TAVR alone significantly improves MR in most patients.
Benjamin E. Peterson, Philippe Généreaux, Pinak B. Shah et al.· Circulation. Cardiovascular...· 0 citations
This review highlights well established indications, such as chronic heart failure with reduced ejection fraction and angina, while also examining recent studies that have questioned routine use in certain scenarios.
B. Sperry, Mohammad Abdel Jawad, Deepak L. Bhatt et al.· Journal of the American Coll...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.